Harmony Biosciences Holdings Inc [HRMY] stock prices are up 6.98% to $32.05 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HRMY shares have gain 8.87% over the last week, with a monthly amount glided 9.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Harmony Biosciences Holdings Inc [NASDAQ: HRMY] stock has seen the most recent analyst activity on February 11, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $55. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 17, 2024, and set its price target to $75. UBS started tracking the stock assigning a Buy rating and suggested a price target of $56 on September 10, 2024. Citigroup initiated its recommendation with a Buy and recommended $48 as its price target on June 21, 2024. BofA Securities downgraded its rating to Underperform for this stock on January 02, 2024, but kept the price target unchanged to $30. In a note dated September 25, 2023, Goldman downgraded an Sell rating on this stock and revised its target price from $40 to $31.
The stock price of Harmony Biosciences Holdings Inc [HRMY] has been fluctuating between $26.47 and $41.61 over the past year. Currently, Wall Street analysts expect the stock to reach $48 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $32.05 at the most recent close of the market. An investor can expect a potential return of 49.77% based on the average HRMY price forecast.
Analyzing the HRMY fundamentals
The Harmony Biosciences Holdings Inc [NASDAQ:HRMY] reported sales of 744.85M for trailing twelve months, representing a surge of 19.48%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.21%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 0.24 and Total Capital is 0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.47 points at the first support level, and at 28.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.98, and for the 2nd resistance point, it is at 33.91.
Ratios To Look Out For
It’s worth pointing out that Harmony Biosciences Holdings Inc [NASDAQ:HRMY]’s Current Ratio is 3.67. As well, the Quick Ratio is 3.63, while the Cash Ratio is 2.79. Considering the valuation of this stock, the price to sales ratio is 2.47, the price to book ratio is 2.55 and price to earnings (TTM) ratio is 12.22.
Transactions by insiders
Recent insider trading involved Kapadia Sandip, CHIEF FINANCIAL OFFICER, that happened on Apr 01 ’25 when 6987.0 shares were sold. Officer, SANDIP KAPADIA completed a deal on Apr 01 ’25 to buy 6986.0 shares. Meanwhile, CHIEF COMMERCIAL OFFICER Dierks Jeffrey sold 4869.0 shares on Mar 03 ’25.
